Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
from GRACEcast Radiation Oncology Audio Hosted by cancerGRACE - H. Jack West, MD
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of GRACEcast Radiation Oncology Audio?
This episode is 7 minutes long.
When was this GRACEcast Radiation Oncology Audio episode published?
This episode was published on July 17, 2014.
Can I download this GRACEcast Radiation Oncology Audio episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.